Oxytocin (Nasal).

High-affinity agonist binding at the oxytocin receptor is magnesium dependent, with divalent magnesium acting as a cofactor at the binding site. Adequate magnesium status is part of the background chemistry oxytocin signalling relies on.

The body's own oxytocin is finished by peptidylglycine alpha-amidating monooxygenase, an ascorbate-dependent enzyme that places the terminal amide needed for activity. Vitamin C is the reducing cofactor that keeps that step turning over.

The amidating enzyme that finishes endogenous oxytocin is a copper-containing monooxygenase, so copper sits alongside ascorbate at the same catalytic step. Copper status is the metal half of that cofactor pair.

Two randomised trials from the same group gave intranasal oxytocin together with a probiotic and reported on gut brain axis signalling and autonomic measures in young participants. This is one of the few places where a nasal peptide has actually been co-administered with a supplement under randomisation rather than paired on theory. The endpoints are signalling and autonomic markers, and the participant groups were small and specific.

The combination trials of intranasal oxytocin with a probiotic used defined bacterial preparations, and lactobacilli are the class most often carried in them. A different strain is not automatically the same intervention, which is why the confidence sits below the trial itself. The proposed route is vagal and metabolite signalling from the gut toward central oxytocin pathways.

Bifidobacteria are recognised contributors to the vagal and metabolite signalling the oxytocin plus probiotic trials measured, but this species was not itself the tested intervention. The pairing is an extension of the trial logic rather than a replication of it. Early, and strain specific.

A 2025 study administered oxytocin and zinc sulphate to adult men in a supervised opioid substitution programme and measured reproductive indices. Reproductive indices are laboratory and semen measures, not outcomes, and the population is narrow. It is nonetheless a real co-administration rather than an inferred one.

Oxytocin has weak activity at the vasopressin V2 receptor, so at higher exposures it can reduce free water clearance. Combined with a large free water intake that lowers serum sodium, which is well documented for oxytocin given in obstetric settings. This is the safety relevant interaction to know and it concerns water and sodium handling rather than any supplement effect.

Galactooligosaccharides selectively feed bifidobacteria and shift the fermentation metabolites that reach vagal afferents, the signalling route the oxytocin plus probiotic trials were built around. The prebiotic changes the substrate rather than delivering the organism. No trial has combined a prebiotic with intranasal oxytocin.

Inulin fermentation yields short chain fatty acids that act on gut endocrine and vagal signalling, the pathway invoked in the oxytocin plus probiotic work. That places it upstream of the same route without touching the oxytocin receptor. Early mechanistic pairing only.

Oxytocin release follows a diurnal pattern and interacts with the hypothalamic circuits melatonin signals into, and both are used in the evening. Nothing has measured the two together in people. Listed as an overlap in timing and site rather than a demonstrated interaction.

Theanine modulates glutamatergic and GABAergic tone while oxytocin acts through its own G protein coupled receptor, so the two act at different sites on overlapping circuits. The pairing is practical rather than mechanistic. No combination data.

Central oxytocin signalling recruits GABAergic interneurons in several of the circuits it acts on, which is part of why its effects are state dependent. Orally taken GABA has poor central access, so the theoretical overlap and the practical one differ. Early, and the route of the supplement is the weak link.

Vitamin D receptors are present in hypothalamic tissue including regions that express oxytocin, and vitamin D signalling is a background regulator of many neuropeptide genes. That makes vitamin D status a permissive condition rather than an interacting agent. Early, mechanistic, and untested as a combination.

Both are hypothalamic peptides with reproductive and social signalling roles, and oxytocin neurons in the paraventricular nucleus receive input from kisspeptin expressing populations. Each has been given separately in research and neither has been given with the other. Early, and interesting mainly as neuroanatomy.

High affinity agonist binding at the oxytocin receptor is magnesium dependent and is further modulated by membrane cholesterol, a long established feature of this receptor. Whole body magnesium status is not the same variable as local divalent cation concentration at a receptor, so the practical reach of a supplement here is limited. The biochemistry is settled; the supplement inference is not.